Quarterly report [Sections 13 or 15(d)]

Revenues from Contracts and Significant Customers

v3.26.3
Revenues from Contracts and Significant Customers
 9 Months Ended
Sep. 30, 2026
Revenues from Contracts and Significant Customers  
Revenues from Contracts and Significant Customers

17. Revenues from Contracts and Significant Customers

Disaggregation of Net Revenue

Journey has the following actively marketed products: Emrosi, Qbrexza, Amzeeq, Zilxi, Accutane, Exelderm, Targadox, Luxamend, and Eurax. All of Journey’s product revenues are recorded in the U.S. 

​

The table below summarizes the Company’s net revenue for the periods presented:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three months ended September 30, 

​

Nine Months Ended September 30, 

($ in thousands)

  ​ ​ ​

2026

  ​ ​ ​

2025

  ​ ​ ​

2026

  ​ ​ ​

2025

Emrosi

​

$

9,002

​

$

4,883

​

$

23,329

​

$

9,748

Qbrexza

​

​

5,590

​

​

7,361

​

​

15,732

​

​

19,470

Accutane

​

​

3,023

​

​

2,769

​

​

9,694

​

​

9,818

Foam franchise products (Amzeeq & Zilxi)

​

​

942

​

​

1,311

​

​

2,933

​

​

3,973

Eurax

​

​

105

​

​

—

​

​

225

​

​

—

Other / legacy product revenue

​

​

263

​

​

701

​

​

772

​

​

2,164

Other revenue

​

​

234

​

​

606

​

​

1,229

​

 

2,010

Total net revenue

​

$

19,159

​

$

17,631

​

$

53,914

​

$

47,183

​

Other revenue for the three months ended September 30, 2026 primarily consists of royalty revenue of $0.2 million recognized by Cyprium related to sales of ZYCUBO (see Note 3).

​

Other revenue for the nine months ended September 30, 2026 consisted of $0.8 million recognized by Journey related to the Cutia Agreement (see Note 8), including $0.1 million recognized in royalties on sales of Amzeeq by Cutia, and royalty revenue of $0.5 million recognized by Cyprium related to sales of ZYCUBO (see Note 3).

​

Other revenue for the three and nine months ended September 30, 2025 consisted of revenue recognized by Avenue related to the AJ201 license termination and program transfer (see Note 8) of nil and $1.4 million, respectively, and $0.6 million and $0.6 million recognized by Journey related to the Cutia Agreement (see Note 8), respectively.

​

Significant Customers

For the three and nine months ended September 30, 2026 and 2025, none of Journey’s dermatology products customers accounted for more than 10% of its total gross product revenue.

At September 30, 2026 and December 31, 2025, none of Journey’s dermatology products customers accounted for more than 10% of its total accounts receivable balance.